.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Risedronate sodium - Generic Drug Details

« Back to Dashboard
Risedronate sodium is the generic ingredient in three branded drugs marketed by Teva Pharms Usa, Macleods Pharms Ltd, Apil, Apotex Inc, Mylan Pharms Inc, Sun Pharma Global, and Aurobindo Pharma Ltd, and is included in ten NDAs. There are ten patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has two hundred and fifty-three patent family members in fifty-two countries.

There are nineteen drug master file entries for risedronate sodium. Ten suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: risedronate sodium

Tradenames:3
Patents:10
Applicants:7
NDAs:10
Drug Master File Entries: see list19
Suppliers / Packaging: see list10
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: risedronate sodium

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate

Tentative approvals for RISEDRONATE SODIUM

Applicant Application No. Form Dosage
<disabled><disabled>TABLET;ORAL35MG
<disabled><disabled>TABLET;ORAL30MG
<disabled><disabled>TABLET;ORAL35MG

Clinical Trials for: risedronate sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL200477-003Nov 30, 2015RXNo<disabled><disabled>
Mylan Pharms Inc
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL200477-004Jun 10, 2014RXNo<disabled><disabled>
Macleods Pharms Ltd
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL203533-001Dec 9, 2015RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: risedronate sodium

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-004Apr 16, 20075,583,122*PED<disabled>
Apil
ATELVIA
risedronate sodium
TABLET, DELAYED RELEASE;ORAL022560-001Oct 8, 20105,583,122*PED<disabled>
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-001Mar 27, 19985,583,122*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: risedronate sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,569,460 Film-coated tablet for improved upper gastrointestinal tract safety<disabled in preview>
8,535,718Dosage forms of bisphosphonates<disabled in preview>
6,544,967 Method for inhibiting bone resorption<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: risedronate sodium

Country Document Number Estimated Expiration
Germany01201913<disabled in preview>
Serbia49979<disabled in preview>
European Patent Office1175904<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RISEDRONATE SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007 00045Denmark<disabled>
2006 00005Denmark<disabled>
222Luxembourg<disabled>91222, EXPIRES: 20200824
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc